RXRA and hepatocellular carcinoma: Interestingly, clinical trial of acyclic retinoid, a synthetic analog of retinoids that target at phosphorylated RXRα, revealed a promising effect in reducing the incidence rate of secondary HCC by about 20% 47, 48.